The COVID-19 beneficiary Pfizer Inc. (PFE) surpassed its EPS estimates by a mammoth 27% in the 2022 third quarter, despite overall market uncertainties and rising recession odds.
PFE possesses sturdy fundamentals. Moreover, the U.S. Food and Drug Administration granted Emergency Use Authorization to PFE and BioNTech SE’s (BNTX) Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children aged six months to 4 years of age. The company is expected to continue to benefit from its vaccines.
